Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

List of Claims:

1. (Currently amended) A fusion protein comprising
i) A first polypeptide sequence which is at least 70% identical to ~~derived from~~ a lectin-complement pathway activating protein ~~or a functional homologue at least 70% identical to said lectin-complement pathway activating protein,~~ or to a fragment, comprising at least thirty consecutive amino acids, of a lectin-complement pathway activating protein, wherein said first polypeptide sequence is capable of activating the lectin-complement pathway; and
ii) A second polypeptide sequence which is at least 70% identical to ~~derived from~~ a collectin ~~or a functional homologue at least 70% identical~~ or to a fragment, comprising at least thirty consecutive amino acids, of a ~~to said~~ collectin, wherein said second polypeptide sequence is capable of associating with one or more carbohydrates;
wherein said complement activating protein is not a collectin.

2. (Cancelled)

3. (Original) The fusion protein according to claim 1, wherein said first polypeptide sequence is capable of associating with at least one MASP protein.

4. (Original) The fusion protein according to claim 1, wherein said first polypeptide sequence is capable of associating with a MASP protein selected from the group consisting of MASP-1, MASP-2 and MASP-3 or functional homologues or variants hereof.

5. (Original) The fusion protein according to claim 1, wherein the complement activating protein is a ficolin.

6. (Original) The fusion protein according to claim 5, wherein the ficolin is selected from the group consisting of L-ficolin, H-ficolin and M-ficolin.

7. (Original) The fusion protein according to claim 5, wherein the ficolin is L-ficolin.

8. (Cancelled)

9. (Currently amended) The fusion protein according to claim 1, wherein the first polypeptide sequence comprises a sequence which is at least 70% identical to the collagen-like domain of a ficolin ~~or a functional homologue or variant thereof~~.

10. (Cancelled)

11. (Currently amended) The fusion protein according to claim 1, wherein the first polypeptide sequence comprises a sequence which is at least 70% identical to the cysteine-rich region of a ficolin ~~or a functional homologue thereof~~.

12. (Cancelled)

13. (Currently amended) The fusion protein according to claim 1, wherein the first polypeptide sequence comprises sequences which are at least 70% identical to the cysteine-rich region and the collagen-like domain of a ficolin ~~or a functional homologue or variant thereof~~.

14. (Cancelled)

15. (Previously presented) The fusion protein according to claim 1, wherein the first polypeptide sequence comprises amino acids 1-77 of the L-ficolin sequence of figure 1 (SEQ ID. NO 125).

16. (Cancelled)

17. (Original) The fusion protein according to claim 1, wherein the collectin is selected from the group consisting of MBL (mannose-binding lectin), SP-A (lung surfactant protein A), SP-D (lung surfactant protein D), BK (or BC, bovine conglutinin) and CL-43 (collectin-43).

18. (Original) The fusion protein according to claim 17, wherein the collectin is MBL.

19. (Cancelled)

20. (Currently amended) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises a

sequence which is at least 70% identical to the CRD domain of a collectin ~~or a functional homologue or variant thereof~~.

21. (Original) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the CRD domain of MBL.

22. (Original) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the neck region of MBL.

23. (Original) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the collagen-like domain of MBL.

24. (Original) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the neck region and the CRD domain of MBL.

25. (Original) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the collagen-like domain, the neck region and the CRD domain of MBL.

26. (Previously presented) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises amino acids 80-228 of the MBL sequence shown in figure 2 (SEQ ID. NO 126).

27. (Currently amended) The fusion protein according to claim 1, wherein the fusion protein comprises the ~~the~~ cysteine-rich region and the collagen-like domain of L-ficolin and the CRD domain of MBL.

28. (Original) The fusion protein according to claim 1, wherein the fusion protein comprises the cysteine-rich region of L-ficolin and the collagen-like domain, the neck region and the CRD domain of MBL.

29. (Currently amended) The fusion protein according to claim 1, wherein the fusion protein comprises ~~the~~ an amino acid sequence which is at least 70% identical to ~~as defined by~~ the sequence shown in figure 3 (SEQ ID. NO. 127).

30. (Previously presented) The fusion protein according

to claim 1, wherein the fusion protein consists of the amino acid sequence as defined by the sequence shown in figure 3 (SEQ ID. NO. 127).

31. (Withdrawn) An isolated nucleic acid comprising a nucleotide sequence encoding the fusion protein according to claim 1.

32. (Withdrawn) A vector comprising the nucleic acid sequence according to claim 31.

33. (Withdrawn) A cell comprising the vector according to claim 32.

34-36. (Cancelled)

37. (Withdrawn) A method of prevention and/or treatment of an infection in an individual in need thereof comprising administering to said individual an effective amount of the fusion protein according to claim 1.

38. (Cancelled)

39. (Withdrawn) The method according to claim 37, wherein the individual is a human being.

40. (Withdrawn) The method according to claim 37, wherein the individual is a human being suffering from an increased risk of acquiring an infection.

41. (Withdrawn) The method according to claim 37, wherein the individual is a human being with subnormal serum MBL level.

42. (Withdrawn) The method according to claim 37, wherein the individual is a human being with normal serum MBL level.

43-48. (Cancelled)

49. (Withdrawn) A pharmaceutically acceptable composition for the treatment or prevention of a clinical condition in an individual in need thereof, comprising the fusion protein according to claim 1, and a pharmaceutically acceptable carrier.

50-51. (Cancelled)

52 (new). The fusion protein of claim 1, comprising

i) a first polypeptide sequence which is at least 95% identical to a ficolin and
ii) a second polypeptide sequence which is at least 95% identical to a Mannose Binding Lectin, a precursor of a Mannose Binding Lectin or a Mannose Binding Lectin like polypeptide.

53 (new). The fusion protein of claim 52, comprising ii) a second polypeptide sequence which is at least 95% identical to MBL.

54 (new). The fusion protein of claim 52 comprising i) a first polypeptide sequence which is at least 95% identical to a ficolin of any of SEQ ID NO: 128 to 147 and ii) a second polypeptide sequence which is at least 95% identical to a Mannose Binding Lectin, a precursor of a Mannose Binding Lectin or a Mannose Binding Lectin like polypeptide of SEQ ID NO 2, 3, 8, 9, 15, 16, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38 or 40.

55 (new). The fusion protein of claim 52, wherein the ficolin is mature human L-ficolin (SEQ ID 125) and the second polypeptide sequence is at least 95% identical to the MBL of SEQ ID 2.

56 (new). The fusion protein of claim 52, wherein the first polypeptide sequence comprises at least five instances of the motif X-G-X-X-G, which instances may be the same or different.

57 (new). The fusion protein of claim 1 wherein the first polypeptide sequence is at least 70% identical to a lectin-complement pathway activating protein, or to a fragment, comprising at least fifty consecutive amino acids, of such a protein, and the second polypeptide sequence is at least 70% identical to a collectin, or to a fragment, comprising at least fifty consecutive amino acids, of such a protein.

58 (new). The protein of claim 57 in which the lectin-

complement pathway activating protein is human L-ficolin (SEQ ID NO:125) and the collectin is human mannose-binding lectin (SEQ ID NO:126).

59 (new). The fusion protein of claim 1 wherein the first polypeptide sequence is at least 95% identical to a lectin-complement pathway activating protein, or to a fragment, comprising at least fifty consecutive amino acids, of such a protein, and the second polypeptide sequence is at least 95% identical to a collectin, or to a fragment, comprising at least fifty consecutive amino acids, of such a protein.

60 (new). The protein of claim 59 in which the lectin-complement pathway activating protein is human L-ficolin (SEQ ID NO:125) and the collectin is human mannose-binding lectin (SEQ ID NO:126).

61 (new). The method of claim 57 wherein the first polypeptide sequence differs from the corresponding sequence of said lectin-complement pathway activating protein, a fragment thereof, solely by one or more conservative substitutions, and said second polypeptide sequence differs from the corresponding sequence of said collectin, or fragment thereof, solely by one or more conservative substitutions.

62 (new). The protein of claim 61 in which the lectin-complement pathway activating protein is human L-ficolin (SEQ ID NO:125) and the collectin is human mannose-binding lectin (SEQ ID NO:126).

63 (new). The method of claim 59 wherein the first polypeptide sequence differs from the corresponding sequence of said lectin-complement pathway activating protein, a fragment thereof, solely by one or more conservative substitutions, and said second polypeptide sequence differs from the corresponding sequence of said collectin, or fragment thereof, solely by one or more conservative substitutions.

64 (new). The protein of claim 63 in which the lectin-complement pathway activating protein is human L-ficolin (SEQ

ID NO:125) and the collectin is human mannose-binding lectin (SEQ ID NO:126).